Article
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
The Lancet. Oncology - 1 Oct 2008
Linardou Helena, Dahabreh Issa J, Kanaloupiti Dimitra, Siannis Fotios, Bafaloukos Dimitrios, Kosmidis Paris, Papadimitriou Christos A, Murray Samuel
Abstract excerpt
BACKGROUND: Somatic mutations of the k-RAS oncogene have been assessed as a mechanism of de-novo resistance to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibition in patients with non-small-cell lung cancer (NSCLC), and to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer (mCRC). The aim of this systematic review and meta-analysis was to assess if k-RAS mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.